CryoBiomed is an spin-off company from the CryoBiotech group at the Universidad de Sevilla (Spain), placed into the Engineers School at the Cartuja Campus, an ideal environment to develop research projects boosting multidisciplinary interactions with a wide range of technological companies and academic groups. Several companies from the Aero-space, IT and Biomedical sectors have chosen this campus to place their headquarters. The city holding the warmest climate in Europe hosts the development of benchmark ultra-low temperatures-based technologies.
We are working as well at the Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII), the main Public Research Entity funding, managing and carrying out biomedical research in Spain.
The Institute has been conducting research and providing key services in the life and health sciences for over 20 years. It is also the body responsible for managing Spain’s Health Research and Development Strategy within the framework of the National R+D+I Plan.
Reports directly to the Ministry of Economy and Competitiveness (Royal Decree 345/2012) and in operational terms to both this Ministry and to the Ministry of Health, Social Services and Equality (Royal Decree 200/2012), has as its main mission to support the development of scientific knowledge in the health sciences and to contribute to innovation in healthcare and the prevention of disease.
Cryopreservation is an state-of-the-art technology that has proven to be useful for long term storage of biological samples preserving their biological activity. Nowadays, cryopreservation of blood cells, ovules, spermatozoids and embryos is usually used with medical purposes, whereas its application for complex tissues and organs is still to be investigated and is the main goal of CryoBiomed. Several approaches are being assessed to improve the treatment of the organ during the process. Computerized Tomography enables the real time monitoring of the cryo-protectant perfusion process and electromagnetic rewarming guarantees a quick thawing to reactivate the organ.
To achieve these aims, CryoBiomed is enhancing the R&D activity in a wide range of methodologies such as electromagnetic rewarming, for deep frozen specimens, or the use of Computerized Axial Tomography to monitor the perfusion of organs with cryoprotectants before the application of the ultra-low temperature.
In this way we established the following phases:
1.- Studies of macroscopic level of vitrified mouse heart after overheating. It would consist in the evaluation of organoleptic properties by direct observation of the organ.
2.- Histological studies. This will require the help of a pathology specialist.
3.- Electrophysiological studies, which could possibly be developed in two stages:
a) ex vivo, using a Langendorff device and
b) in vivo, through ectopic transplantation and direct examination of the animal.
Meet CryoBiomed next summer (10-13 July) in Madrid at: